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Abstract Trilateral retinoblastoma (TRb) is a rare dis-
ease associating intraocular retinoblastoma with intracra-
nial primitive neuroectodermal tumor. Treatment is
difficult and prognosis is poor. This multicenter study
evaluates clinical findings and MR imaging characteristics
of associated intracranial tumors in Rb patients. Clinical
data of 17 patients (16 TRb and 1 quadrilateral Rb patients)
included time intervals between Rb and TRb diagnosis and
presence of baseline brain-imaging (BBI). Two reviewers
reviewed all images individually and one reviewer per
center evaluated their images. Consensus was reached
during a joint scoring session. Studies were reviewed for
tumor location, size and imaging characteristics (signal
intensity (SI) on T1- and T2-weighted images, enhance-
ment pattern and cystic appearance). Of 18 intracranial
tumors, 78 % were located in the pineal gland and 22 %
suprasellar. All tumors showed well-defined borders with
mostly heterogenous enhancement (72 %) and isointense
SI on T1- (78 %) and T2-weighted images (72 %) com-
pared to gray matter. The majority of pineal TRbs showed
a cystic component (57 %). TRb detected synchronously
with the intraocular tumors on BBI (n = 7) were signifi-
cantly smaller (P = 0.02), and mainly asymptomatic than
TRb detected later on (n = 10). Overall, 5-year-survival of
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TRb patients detected on BBI was 67 % (95 % CI
29–100 %) compared to 11 % (95 % CI 0–32 %) for the
group with delayed diagnosis. TRb mainly develops in the
pineal gland and frequently presents with a cystic appear-
ance that could be misinterpreted as benign pineal cysts.
Routine BBI in all newly diagnosed Rb patients can detect
TRb at a subclinical stage.
Keywords Trilateral retinoblastoma  Pineoblastoma 
MR imaging  Pediatric oncology  Head and neck
Introduction
Trilateral retinoblastoma (TRb) is a disease associating
unilateral or bilateral retinoblastoma (Rb) with an intra-
cranial midline primitive neuroectodermal tumor (PNET)
which usually arises in the pineal gland (PG) (77 %) [1]. In
hereditary Rb patients, the neural ectoderm destined to form
both retinal and pineal tissue is prone to develop multifocal
neoplasms. This results in histological similar but separate
located tumors [2]. The risk of developing TRb in Rb
patients is less than 0.5 % for sporadic unilateral disease
[3], 5–13 % in sporadic bilateral disease, and 5–15 % in
familial bilateral Rb [1]. Patients with TRb frequently
present with signs of intracranial hypertension [3–7]. Few
long-term survivors are reported, and, especially in symp-
tomatic patients, prognosis is poor [1, 3, 8–10].
Previous studies on TRb detection, neuroimaging
screening, and prognosis all focused on time intervals
between detection of Rb and TRb (metachronous tumor
development) [1, 10–13]. Reported median time between
Rb and TRb diagnosis is 21 months [1, 3, 9, 10]. However,
Kivela et al. [1] reported tha,t with inclusion of brain MR
screening during first MRI examination for Rb (i.e., base-
line brain imaging; BBI), approximately 50 % of TRb
cases can potentially be found. These are considered syn-
chronous tumors, detected on baseline MRI. Approxi-
mately another 25 % of TRbs can be found during the first
year after Rb detection. However, recent literature states
that TRb is rarely present at diagnosis of Rb [14]. We
hypothesize that the exact prevalence of synchronous
occurrence of TRb and Rb in literature is underestimated.
In most studies, it remains unclear whether BBI was per-
formed at Rb diagnosis, at some time-point during follow-
up or only in a later stage for detection of symptomatic
TRb; and if imaging was performed with CT or MR. This
complicates the evaluation of ‘‘true’’ synchronous TRb in
literature.
Only few radiological articles on TRb have been
reported, and these were mainly individual case reports. To
our knowledge, only two studies described radiologic
findings on MRI in trilateral retinoblastoma, both within
small groups of patients [10, 15]. Because of these modest
study populations, it is relevant to identify specific MRI
characteristics of TRb in a larger group of patients.
The primary purpose of this multicenter study was to
evaluate clinical findings and MRI characteristics of asso-
ciated intracranial tumors in Rb patients. The secondary
purpose was to assess clinical, radiological and prognostic
differences between TRb depicted on BBI and those
depicted later on.
Materials and methods
Patient population
This retrospective study was performed in agreement with
the recommendations of the local ethics committees
within a European Retinoblastoma Imaging Center (ERIC)
with five participating Rb centers. Review of clinical
records between 1991 and 2010, revealed 17 Rb patients
with MRI and intracranial tumors. TRb was diagnosed on
the basis of histopathological confirmation [surgery or
presence of tumor cells in cerebrospinal fluid (CSF)] or
clinical disease progression during follow-up MRI. TRb
was defined as a mass lesion in the PG or suprasellar
region in Rb patients. Tumor in both PG and suprasellar
regions in combination with bilateral Rb was classified as
a quadrilateral Rb (QRb).
Record review
Clinical records were reviewed for tumor laterality, family
history for Rb, age of Rb diagnosis, time interval from Rb
to TRb diagnosis and TRb diagnosis to death or last follow-
up date. Symptoms at first presentation of TRb and treat-
ment received for Rb and TRb were recorded. Laboratory
records were analyzed for tumor cells in CSF acquired by
lumbar puncture (LP) performed either at diagnosis or
during follow-up. Particular attention was paid to the
presence of BBI, which is necessary to evaluate the
simultaneous occurrence of TRb at Rb diagnosis. TRbs
were categorized in synchronous or metachronous tumors
to the intraocular tumor. Patients with bilateral retino-
blastoma, a positive family history of retinoblastoma or
mutations in the RB1 gene found in chromosomal/DNA
analysis were classified as hereditary. Disease progression
was defined as either tumor recurrence, intracranial or
intraspinal leptomeningeal spread or distant metastases.
Image review
Patients underwent various imaging protocols for the
assessment of TRb. MRI sequences varied in different
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institutions. Brain MRI protocols at least included either
sagittal or transverse unenhanced T1-weighted images or
T2-weighted images in 14 patients. Post-contrast T1-
weighted images of TRb were available in 16 patients.
Two observers (JC and PdG) with, respectively, 22 years
and 10 years experience individually reviewed all MRI
examinations and one radiologist from each participating
center (HJB, PG, PM and SG) evaluated their images.
Agreement was reached during a joint scoring session. MR
images were evaluated for mass lesions in the PG and
suprasellar regions and for leptomeningeal tumor dissem-
ination. Regarding the TRb, maximal axial diameter
(MAD) at diagnosis, tumor border, presence of tumor
necrosis, tumor aspect (solid, solid with cystic component,;
or complete cystic), SI on T1- and T2-weighted images
compared to gray matter, aspect of contrast enhancement,
presence of vessel encasement, and hydrocephalus and
leptomeningeal metastases were scored.
Statistics
Statistical calculations were performed using SPSS v.15.0
(SPSS, Chicago, IL, USA). BBI and MAD were analyzed
by using the Mann–Whitney test. Difference in mean MAD
between pineoblastomas and suprasellar tumors was ana-
lyzed using an independent t test. Associations between
other clinical dichotomous parameters and BBI were
assessed using Fisher exact tests. A 95 % CI for 5-year
survival was calculated based upon the Kaplan–Meier
survival function. A P value of less than 0.05 was con-
sidered statistically significant.
Results
Clinical findings
Clinical data of part of this study have been previously
reported (Table 1) [1]. Ten patients had familial Rb (59 %)
and 11 patients also a positive RB1-gene mutation (65 %).
Sixteen patients (94 %) were classified as hereditary Rb.
Mean age of Rb diagnosis was 9 months (median age
5 months) and of TRb 26 months (median age,
23 months). Mean time-interval between detection of Rb
and TRb was 18 months (median, 14 months). In none of
the patients, TRb was found before Rb.
Nine patients had signs of intracranial hypertension,
whereas the other 8 patients were asymptomatic at
Table 1 Clinical patient characteristics
Patient
(Rb lat)
Confirmation
TRb
Age
Rb
Age
TRb
Int. Rb–
TRb
Year Rb
date
BBI Death Int TRb
death
Int TRb
FU
Treatment RB
(OD; OS)
Treatment
TRb
1 (B) Histopathology 3 52 49 1986 No Yes 57 57 PT ChT, EBRT
2 (B) CSF 2 39 37 1990 No Yes 21 21 EBRT ChT, EBRT
3 (B) Histopathology 5 10 5 1991 No Yes 7 7 En; EBRT Palliation
4 (B) DP on MR 23 38 15 1992 No Yes 0 0 EBRT Palliation
5 (B) CSF 2 26 24 1992 No Yes 13 13 CrT; En. ChT
6 (B) DP on MR 12 12 0 1997 Yes Yes 14 14 CrT, En. No
7 (U) CSF 3 57 54 1997 No No 93 No; En. ChT
8 (B) Histopathology 2 42 40 1998 No Yesa 11 11 ChT ChT, EBRT,
surgery
9 (B) DP on MR 3 3 0 2000 Yes No 74 ChT/CrT; En. ChT
10 (B) CSF 17 17 0 2001 Yes Yes 7 7 ChT ChT
11 (B) CSF 3 15 12 2001 No NAb 3 CrT; En. ChT
12 (B) CSF 7 23 16 2002 No Yes 16 16 En; En ChT
13 (B) CSF 1 31 30 2002 No Yes 15 15 ChT; CrT ChT, surgery
14 (B) CSF 10 10 0 2003 Yes No 50 ChT ChT
15 (B) CSF 12 12 0 2005 Yes No 63 ChT, CrT; ChT
16 (U) Histopathology 10 10 0 2006 Yes No 56 ChT ChT, surgery
17 (U) No 38 38 0 2008 Yes NA NA NA No; En. NA
Rb lat laterality Rb, B bilateral Rb, U unilateral Rb, Int. Rb–TRb interval between Rb and TRb in months, Int TRb death interval TRb and death in
months, Int TRb FU interval of follow-up in months, CSF cerebrospinal fluid, DP disease progression, BBI baseline brain imaging, PT plaque
therapy, ChT chemotherapy, EBRT external beam radiation therapy, CrT cryotherapy, NA not available
a Due to intoxicity after chemotherapy
b Lost to follow-up after 3 months with progressive disease
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detection. LP at baseline were performed in 7 patients
(positive for tumor cells in 5 patients) and during follow-up
in 11 patients (positive in 5 additional patients). Histo-
pathologic specimens were available in 4 TRbs and were
classified as PNETs. Rb was treated with external beam
radiotherapy (EBRT) (mean age 10 months, median
5 months) in 3 out of 10 metachronous patients. These
patients developed TRb after a mean interval of 19 months
(range 5–37 months). Rb was treated with chemotherapy in
2 out of 10 metachronous TRb patients (mean interval
35 months; range 30–40 months). Treatment for TRb was
initiated in 13 patients. Two patients received palliative
treatment because of tumor spread, one patient was not
treated because of parental refusal, and one patient was lost
of follow-up.
MRI characteristics of TRb
MRI characteristics are summarized in Table 2. In our
group of 17 patients, 18 intracranial tumors were detected.
Of the 14 pineoblastomas, 6 (42 %) showed a com-
pletely solid aspect (Fig. 1a), 4 (29 %) solid with cystic
component (Fig. 2), and 4 (29 %) were completely cystic
with an irregularly thickened rim (Fig. 3). Pineoblastomas
mimicking pineal cysts showed an irregular (patient 6;
Fig. 3a) or thickened (patient 16; Fig. 3c) cyst wall,
sometimes with tiny nodules. Follow-up imaging in patient
6 showed progression of the pineal lesion into a solid tumor
with diffuse leptomeningeal metastases 14 months after
refusal of treatment (Fig. 3b). Patient 16 showed an obvi-
ous solid tumor part on the axial MR images (Fig. 3d).
Secondary hydrocephalus occurred in 8 patients (57 %)
with pineoblastoma (Figs. 1b, 2b) and leptomeningeal
metastases in 3 patients (21 %) (Figs. 1d, 2b). One supra-
sellar tumor showed a homogenous solid aspect with a
cystic component (Fig. 2a).
Overall, the mean MAD was 30 mm (range 9–59 mm).
Clinical and radiological patterns according to time
of diagnosis
BBI was available in 7 cases and in all Rb and TRb were
diagnosed simultaneously (mean age 15 months, median
12 months; range 3–38 months). These 7 patients did not have
any signs of intracranial hypertension at first presentation.
In the remaining 10 patients without BBI, mean interval
between Rb and TRb diagnosis was 27 months (median
24 months; range 5–54 months). Symptoms of intracranial
hypertension occurred in 8 patients. A significant difference
was observed in tumorsize (P = 0.02) and hydrocephalus
(P = 0.002) in favour of patients with BBI. In 1 patient
with TRb, no symptoms occurred, and in 1 QRb patient,
Table 2 Imaging characteristics
Patient Intracranial
tumor
location
MAD Tumor
border
AL Necrosis SIT1 SIT2 Enhancement LM Hydrocephalus VE
1 PG 25 Well defined Solid No NA NA Homogeneous No Yes Yes
2 PG 55 Well defined PC Yes Isointense Hypointense Heterogeneous No Yes Yes
3 PG 59 Well defined PC Yes Isointense Isointense Heterogeneous No Yes Yes
4 PG 49 Well defined PC Yes Hypointense Isointense Heterogeneous Yes Yes Yes
5 PG 18 Well defined Solid No Isointense Hypointense Heterogeneous Yes Yes No
6 PG 9 Well defined Cystic Yes Isointense Isointense Heterogeneous No No No
7 PG 51 Well defined PC Yes Isointense Isointense Heterogeneous Ntb Yes No
8 PG 22 Well defined Solid Yes Isointense Isointense Heterogeneous No Yes No
9 PG 13 Well defined Cystic No NA NA Heterogeneous No No No
10 SS 15 Well defined Solid No Isointense Isointense Homogeneous No No No
11 PG 13 Well defined Solid Yes Isointense Isointense NA Ntb No No
12 PG 11 Well defined Solid Yes NA Isointense Heterogeneous No No Yes
12 SS 44 Well defined Solid No NA Isointense Homogeneous No No Yes
13 PG 33 Well defined Solid Yes Isointense Isointense Heterogeneous Yes Yes No
14 SS 23 Well defined Solid No Isointense Isointense Homogeneous No No No
15 SS 34 Well defined PC Yes Isointense Isointense Heterogeneous Yes No No
16 PG 21 Well defined Cystic Yes Isointense Isointense Heterogeneous No No No
17 PG 11 Well defined Cystic Yes Isointense NA Heterogeneous No No No
PG pineal gland, SS supra sellar, MAD maximal axial diameter, AL aspect lesion, PC partly cystic, NA not available, SI T1 signal intensity on T1-
weighted images compared to gray matter, SI T2 signal intensity on T2-weighted images compared to gray matter, LM leptomeningeal
metasteses, VE vessel encasement
538 J Neurooncol (2012) 109:535–544
123
Fig. 1 Solid pineoblastoma with hydrocephalus and extensive lepto-
meningeal metastases. Sagittal T1-weighted (a), axial T2-weighted
(b), contrast-enhanced sagittal T1-weighted images of the brain
(c) and spine (d) of patient 13. Pineoblastoma showed mostly
isointense SI on both T1-weighted (a) and T2-weighted (b) MR
images with respect to gray matter and homogenous contrast-
enhancement (c). The large tumor mass (33 mm) showed compres-
sion on the brainstem (mesencephalon) and cerebral aquaduct
(a, c) with secondary hydrocephalus (b). Multiple nodular leptome-
ningeal tumor seedings are present in the spinal canal (d)
J Neurooncol (2012) 109:535–544 539
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symptoms could not be retrieved from the clinical records.
Furthermore, other differences were observed in the
patients with BBI compared to patients without BBI. Tumor
size was significantly smaller in patients with BBI [mean
MAD 18 mm (range 9–34 mm)] compared to patients
without BBI [mean MAD 35 mm (range 11–59 mm)]
(P = 0.02). Hydrocephalus (P = 0.002) occurred more
often in patients without BBI and thus in larger tumors.
Lumbar puncture in patients with BBI was positive in 29 %
of the cases and 70 % in patients without BBI (P = 0.15).
In addition, more synchronous tumors were detected
after the year 2000 as illustrated in Table 1, because BBI
was more routinely included in current imaging protocols.
Survival
One out of 17 patients was lost to follow-up and excluded
from survival analysis. One out of the remaining 16
patients was treated with chemotherapy and lost to follow-
up after 3 months with progressive disease, and one died
from intoxicity after intensive chemotherapy.
Five out of 16 patients (33 %) are still alive (mean
survival, 67 months; median 63 months, range, 50–93
months). Four of these 5 patients (80 %) presented with
synchronous TRb detected on BBI and were free of disease
(mean survival, 61 months; range 50–74 months). The
other survivor was diagnosed with a pineoblastoma of
51 mm (54 months after Rb diagnosis without BBI). This
patient had local tumor recurrences but is still in second
complete remission, 93 months after complete resection of
the pineoblastoma and intensive chemotherapy.
The remaining 10 patients died after a mean interval of
24 months. Eight presented with metachronous TRb and
without BBI. Cause of death in these 10 patients included
local spread of the initial TRb (3 patients), leptomeningeal
metastases (4 patients), tumor recurrence (2 patients), and
side effects of intensive chemotherapy (1 patient).
Difference in survival of PNET early detected with BBI
compared to those with delayed diagnosis was not signif-
icant (P = 0.064). The overall 5-year survival of PNET
detected on BBI was 67 % (95 % CI 29–100 %) compared
to 11 % (95 % CI 0–32 %) for the group without BBI.
Discussion
The most important imaging finding of this retrospective
analysis is that the majority of the pineoblastomas in our
study were partially or totally cystic. Other main findings
are that TRbs detected synchronously with the Rb on BBI
Fig. 2 Suprasellar and pineal gland trilateral retinoblastoma. Con-
trast-enhanced axial T1-weighted images showing solid tumor masses
with cystic components in both the suprasellar region (patient 15)
(a) and pineal gland (patient 7) (b). The pineal gland mass causes a
secondary hydrocephalus because of brainstem compression (b)
540 J Neurooncol (2012) 109:535–544
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were significantly smaller, more frequently asymptomatic,
and could have a better prognosis compared to TRbs found
after diagnosis of Rb (metachronous TRBs).
In the literature, the simultaneous occurrence of Rb and
intracranial tumor is rare [14, 16]. Kivela et al. [1] reported
that intracranial tumors were detected before Rb diagnosis
in 3 % of the cases, 14 % simultaneously with Rb, and
83 % after Rb diagnosis. However, the incidence of syn-
chronous TRb is probably underestimated, as historically
little documentation about the presence of BBI at Rb
diagnosis is available. Most TRbs described are diagnosed
after first presentation with symptoms and signs of intra-
cranial hypertension. Diagnosis and treatment for retino-
blastoma is usually completed by then [3–7]. In our study,
in all patients with synchronous tumors detected on BBI,
significantly smaller TRbs were detected compared to
metachronous TRb. Furthermore, 70 % of patients with
metachronous tumors presented with symptoms due to
Fig. 3 Pineoblastoma presenting as suspicious cyst. Contrast-
enhanced sagittal (a–c) and axial (d) T1-weighted images of the
brain in patient 6 (a, b) and patient 16 (c, d). The pineal gland in
a shows an irregular cyst wall with tiny nodules, which progressed
into a solid tumor with diffuse (nodular) leptomeningeal metastases
14 months later after treatment refusal (b). The pineal gland in patient
16 mimics a pineal cyst on the sagittal image (c), but shows a solid
part of the lesion on the axial image (d), suspicious for pineoblastoma
J Neurooncol (2012) 109:535–544 541
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intracranial hypertension and 80 % died due to their
intracranial tumor. This indicates that the majority of
metachronous tumors could have been detected in an ear-
lier stage if BBI would have been performed. Remarkably,
the majority of synchronous tumors were detected in TRb
patients after the year 2000, as cerebral imaging was per-
formed more frequently in our centers. We found a lower
median time-interval of 14 months in our group compared
to a median time interval of 21 months mentioned in
literature [1, 13]. In these studies, however, the majority of
the TRbs (83 and 62 %, respectively) were detected after
diagnosis and treatment for Rb, while in our study a higher
rate of synchronous tumors (41 %) were present.
Pineoblastomas and suprasellar tumors presented as
typically well-defined lesions with relatively isointense SI
on T1-weighted and T2-weighted images compared to gray
matter. Contrast enhancement in these tumors was mostly
heterogenous due to cystic components or tumor necrosis.
Similar SIs on T1-weighted images were reported in 4 and
8 patients, respectively, on MRI [10, 15], but diverse
enhancement patterns and SIs on T2-weighted images have
been described [13, 15, 17, 18]. Hydrocephalus was a
typical complication of large pineoblastomas. Therefore,
we stress the need for BBI to detect smaller TRbs.
The majority of the pineoblastomas in our study were
partially or totally cystic. Pineal cysts have been reported
in Rb patients but not associated with hereditary Rb [19].
The presence of suspicious pineal cystic tumors, however,
are a point of discussion [19–24]. Because of life-threat-
ening side effects that may be related with curative
aggressive treatment in TRb patients [25], it is important
that cysts are not misinterpreted as tumor. Pineal cysts are
diagnosed if (1) an enlarged PG is present, (2) with a
hypointense central region with respect to white matter on
T1-weighted-images and isointense with respect to CSF on
T2-weighted images, and (3) a thin wall of 2 mm or less
with discrete rim enhancement after gadolinium injection
[20]. Although these criteria are formulated, pineal lesions
in retinoblastoma are causing radiological dilemmas,
especially if the cyst wall is irregularly thickened ([2 mm)
or shows a fine nodular aspect of the wall [19, 20]. In our
study, only 6 out of 14 pineoblastomas were completely
solid, whereas 29 % (4 tumors) had both a cystic and solid
component, and 4 tumors mimicked a pineal cyst. Hence,
the need for imaging characteristics of early stage (cystic)
pineoblastoma and follow-up scheme in suspicious cystic
lesions of the PG is necessary to separate these from benign
pineal cysts. Identification of such criteria is only possible
in a large group of suspicious cystic PGs in Rb patients.
Because these tumors are rare, a multicentric prospective
study is necessary to define evident criteria for detection of
early stage (cystic) pineoblastoma. Meanwhile, we rec-
ommend that pineal cystic lesions depicted on BBI should
be classified into three groups: (1) ‘‘probably benign pineal
cyst’’, (2) ‘‘obvious cystic pineoblastoma’’, or (3) ‘‘suspi-
cious pineal cyst’’. The first group contains patients with a
cystic PG with discrete rim enhancement and a thin smooth
wall; we recommend repeating MRI once after 6 months
and, if stable, no further follow-up. The third group
requires close MR follow-up after 3 months. As, currently,
MRI of every new Rb patient is performed routinely in
most centers, screening could easily be obtained by per-
forming at least one brain MR sequence [26]. This
screening could be achieved by a post-contrast 3D
T1-weighted sequence with 1 mm slice thickness, and if a
cystic portion is detected in the PG, an additional 2 mm
T2-weighted sequence or thin slice 3D T2/CISS can further
characterize the lesion.
In our series, a trend was observed for a better survival
of patients who had PNET detected early with BBI.
However, due to the small sample size, this difference did
not reach significance. Several studies advise brain imaging
screening in Rb patients in order to detect TRb in an early
stage [1, 9, 27]. Although improvement of prognosis in
TRb patients is important, caution with screening programs
should be considered. First, prognosis of TRb patients
detected by screening compared to patients with symp-
tomatic disease should be evaluated. Duncan et al. [12]
were the first to evaluate screening for TRb with CT at
baseline and additional brain MRI every 6 months in 83
hereditary Rb patients. No improved outcome was
observed despite early diagnosis. Kivela et al. [1], dis-
covered that screening identified TRb in an earlier stage,
but without better survival. This indicates that longer sur-
vival was due to lead-time bias. A disadvantage of early
detection without better outcome is severe treatment-rela-
ted morbidity and distress in these children leading to
lower quality of life. In recent literature, however, high-
dose chemotherapy has successfully been introduced for
TRb, gradually leading to an increase in survival time [14,
28]. Especially, TRb detected in an early stage could
benefit from these new treatment strategies, since reported
survivors are almost inevitably the synchronous or early
metachronous patients. These early metachronous patients
(TRb diagnosed a few months after Rb diagnosis) should
be classified as ‘‘missed synchronous’’ rather than ‘‘early
metachronous’’. Therefore, we stress the need for routine
brain MRI in every single newly diagnosed retinoblastoma
patient on admission, which is a potentially simple and
(cost-)effective screening method for early TRb detection.
The value of extending brain MRI screening after BBI is
under discussion and therefore sporadically applied in
European retinoblastoma referral centers.
The rare incidence of TRb in all participating Rb centers
in Europe is in agreement with the observed declining
incidence of TRb over the last decades [29–31] and is still a
542 J Neurooncol (2012) 109:535–544
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matter of debate. An increasing use of neoadjuvant che-
motherapy for intraocular retinoblastoma (chemoreduction)
preventing development of TRb has been suggested by
Shields et al. [31], who registered fewer TRb since the
introduction of chemoreduction as primary treatment for Rb.
However, cases of TRb are reported even after an intensive
scheme of chemoreduction therapy in advance [32]. In our
study, 2 out of 10 metachronous TRb patients received
chemotherapy and still developed TRb. The decreasing
incidence of TRb could be due to the declining use of EBRT
in patients with hereditary retinoblastoma [33]. In 3 patients,
intraocular Rb was treated with EBRT, and these patients
developed metachronous pineoblastomas.
A limitation of this study is the absence of BBI in all
included metachronous TRbs. Therefore, the true incidence
of metachronous TRb is still likely to be overestimated.
Also, the small size of our patient cohort was a study
limitation for statistical analysis.
In conclusion, TRb mainly develops in the PG and fre-
quently presents with a cystic appearance that may be
misleading. We recommend a three-group classification of
pineal cystic lesions depicted in Rb patients. Routine BBI in
all newly diagnosed Rb is strongly recommended as it may
detect TRb in a subclinical and potentially curable stage.
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